| Half-life | 12 hours |
| Tmax | 1.5 h |
| Bioavailability | 80 % (approx) |
| Protein Binding | 80 % |
| Volume of Distribution | 1 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Short half-life produces interdose withdrawal; CYP3A4 metabolism; avoid with strong inhibitors. |
Severity: Severe
Adverse Effects:
Sedation, impaired judgment, memory impairment, dependency, withdrawal seizures
Contraindications:
Acute narrow-angle glaucoma, severe respiratory insufficiency
Precautions:
Avoid chronic daily use; taper slowly; avoid with alcohol and opioids.